Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Sarcoma 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 59Cisplatin 45Cetuximab 29Radiotherapy 26Carboplatin 24Docetaxel 17Paclitaxel 16Nivolumab 16Surveys and Questionnaires 15Radiotherapy, Intensity-Modulated 13Fluorouracil 12Drug Therapy 12Blood Specimen Collection 11Standard of Care 8tislelizumab 7cemiplimab 6atezolizumab 6Radiation 6Chemoradiotherapy 6toripalimab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5nimotuzumab 4fludarabine 4durvalumab 4dostarlimab 4Surgical Procedures, Operative 4Afatinib 4palbociclib 3niraparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × EBC-46 × 1 year × Clear all
NCT05608876 2025-08-07

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

QBiotics Group Limited

Phase 2 Active not recruiting
15 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡